Singula Bio

Singula Bio is a seed-stage biotechnology company developing individualised, neoantigen-based cell therapies for patients with solid tumours, with an initial focus on ovarian cancer and other difficult-to-treat malignancies.

The company's approach harnesses a patient's own immune system to target mutations that appear foreign within their tumour, drawing on immunological, medical, surgical and computational techniques to design selective, patient-specific therapies.

Singula Bio aims to achieve long-term, disease-free survival for cancer patients through this individualised treatment model.